Arnon Nagler MD, MSc

Arnon Nagler, M.D., M.Sc., served for many years as a director of both the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Chaim Sheba Medical Center, and Professor of Medicine at The Tel Aviv University, Israel.

Prof. Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel, specializing in Internal Medicine and Haematology at the Rambam Medical Center, Haifa, and in Hematopoiesis (MSc) at TA University, Israel. He carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” in Palo Alto, CA, in the USA, from 1986 to 1990.

Prof. Nagler has been working in the field of bone marrow transplantation for hematological malignancies, for the last 25 years. Prof. Nagler is one of the pioneers of non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998). His main contributions and scientific interests include hematopoietic stem cell transplantation, hematological malignancies, cord blood biology and transplantation, and adoptive cell-mediated immunotherapy including NK cell biology.

Prof. Nagler established the first public cord blood bank in Israel and performed the first cord blood transplantations from related and unrelated donors in genetic and malignant hematological diseases in Israel.

Prof. Nagler has been an active member of the EBMT since 1993. In the 2001 EBMT Annual meeting (Maastricht, the Netherlands) his study on IL-18 for GVHD in mice model was chosen for presentation at the presidential symposium. Over the years he was invited speaker in several of the EBMT meetings. Dr Nagler served as the leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010 and in 2010 he is the leader of the RIC subcommittee of the ALWP of the EBMT.

Prof. Nagler serves on the Board of Directors of the Netcord organization of cord blood banks and was the Netcord Treasurer from 2010-2013. Prof. Nagler is a member of multiple national and international societies and committees in the field. He serves on the Editorial Board of several journals and is the stem cell transplantation Section Editor for Leukemia.

Prof. Nagler has written numerous original articles, reviews, and chapters for ranked peer-reviewed journals including JCO, Blood, JEM, JI, EJI, Leukemia, and many others, and is the principal investigator for multiple clinical studies including first-to-human trials with novel molecules like Pidilizumab (McAb against PD-1) and BL8040 (novel CXCR4 antagonist). Prof. Nagler is the inventor of multiple patents including for the purging of BM with NK cells and inhibition of fibrosis by Halofuginon.

Prof. Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Prof. Nagler is a popular speaker and has made numerous, invited, international presentations and many Oral presentations on an almost annual basis in all international transplantation and hematology meetings – ASH, ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).